Susquehanna International Group, LLP Gain Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2025
A detailed history of Susquehanna International Group, LLP transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 85,958 shares of GANX stock, worth $154,724. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85,958
Previous 46,913
83.23%
Holding current value
$154,724
Previous $95,000
72.63%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.1MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.06 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.02 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$507,9790.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$458,9820.0% of portfolio
-
Marshall Wace, LLP London, X0196KShares$352,8460.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $21.4M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...